Novavax agrees manufacturing deal with Endo for Covid vaccine

Novavax has signed an agreement for Endo International to manufacture its experimental Covid-19 vaccine, which is currently in multiple phase 2 clinical trials.

Endo said on Friday that its Par Sterile unit has begun production at its Rochester facility of the NVX-CoV2373 final drug product, with initial batches to be used in Novavax's pivotal Phase 3 clinical trial in the US.

Par Sterile will also fill-finish NVX-CoV2373 vaccine intended for commercial distribution in the US.

No financial details of the agreement were disclosed.

Stanley C. Erck, president and chief executive officer of Novavax, said: "This agreement puts an important piece in place as we finalise our supply chain for the US clinical trial and eventually, commercial distribution of NVX-CoV2373, our nanoparticle vaccine adjuvanted with Matrix-M™.

"Endo's partnership and expertise are enabling rapid delivery of the vaccine for pivotal clinical testing, which we expect to get underway very soon."

At 1330 BST, Novavax shares were trading up 6.6% in pre-market trade at $108.97.